Cancer Control in the 21st Century with Special Attention to Disparities in Health
Otis W. Brawley, M.D., M.A.C.P., F.R.C.P.
Bloomberg Distinguished Professor
Sidney Kimmel Comprehensive Cancer Center
Department of Epidemiology
Bloomberg School of Public Health
Johns Hopkins University
Elected Member of the National Academy of Medicine
Archived Maury Strauss Distinguished Public Lecture: Cancer Control in the 21st Century with Special Attention to Disparities in Health
Date: September 9, 2021
Time: 5:30 - 6:30 p.m.
Pictures and video from the event
About this Seminar
On December 23, 1971, President Richard Nixon signed the National Cancer Act. It was historic legislation aimed at overcoming one of man’s most dreaded disease. It is often referred to as the nation declaring war on cancer. The law infused unprecedented financial support into cancer research (basic and clinical). Numerous important questions have been asked and many answered. Indeed, the past fifty years have led to a change in our understanding of cancer. We have moved from a 19th century definition of cancer based on histology, to a 21st century definition based on histology and genomics.
Also of import, the law called for a cancer control program. A key part of which was a surveillance system that would establish and manage a program to determine cancer incidence, mortality, survival, and study patterns of cancer care. The surveillance program has documented the successes and failures of the National Cancer Act. It has stimulated the academic field of cancer epidemiology. The effort to control cancer has led to a 31 percent reduction in age-adjusted cancer death rate from 1991 to 2018. This decline is due to prevention (risk reduction), appropriate screening, diagnosis, and treatment. While there have been successes, all have not benefited equally. An efficient health system could have caused an even greater decline. The National Cancer Act stimulated the academic field of health disparities/health equity. Research suggests that more than 20 percent of the 600,000 cancer deaths per year are avertable in an efficient healthcare system.
The National Cancer Act has defined a number of questions pertinent to the control of cancer. Perhaps the most important question is: "How can we provide adequate, high-quality care, to all Americans.”
Additional Details
This is a free event hosted by Dr. Michael Friedlander and the Fralin Biomedical Research Institute. For more information, please call 540-526-2059.
About Maury Strauss
Maury Strauss is a longtime community benefactor and businessman who supports biomedical research with the goal of energizing the local economy and improving quality of life in our neighborhoods and around the world. In order to ensure the continued success of Roanoke’s biomedical research enterprise, as well as the free public seminars, Mr. Strauss has made a generous gift to the series. Read VT News Story
Support Our Research
Your generous support of the Fralin Biomedical Research Institute's rigorous biomedical research enterprise makes a difference for our faculty, students, and patients. Every donation helps accelerate the pace of new discoveries to help patients with cancer, neurological disorders, heart disease, and even rare genetic disorders. Private donations fast-track our progress.
You May Also Be Interested In...
-
Home ItemSeminar: Precision Medicine of Biological Drugs for Brain Cancer , home
Dec. 7, 2023, 11 a.m. | Professor, Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine | Seminar | Children's National Research and Innovation Campus
-
Home ItemIn Person at CNRIC: Hyperactivation of an RNA Binding Protein by Cancer-associated Mutations , home
POSTPONED: Dec. 8, 2023, 11:00 a.m., Collaboratory, Children's National Research and Innovation Campus, Washington, D.C. | Daniel Dominguez, Ph.D., Assistant Professor, Pharmacology, UNC School of Medicine | Co-Sponsored by the Fralin Biomedical Research Institute Cancer Research Group
-
Home ItemIn Person Seminar: An Epigenome Atlas of the Embryonic Mouse Brain to Study Interneuron Neurogenesis in Normal Development and Disease Models , home
Dec. 15, 2023, 11:00 a.m. | Timothy Petros, Ph.D., Investigator, Unit on Cellular and Molecular Neurodevelopment, Eunice Kennedy Shriver National Institute of Child Health & Human Development, National Institutes of Health | Co-Sponsored by the Fralin Biomedical Research Institute Center for Neurobiology Research
-
Home ItemIn Person Seminar: Quantitative Proteomics for Understanding Epigenetic Cancer Mechanisms , home
Jan. 12, 2024, 11 a.m. | Ben Garcia, Ph.D., Raymond H. Wittcoff Distinguished Professor and Head, Department of Biochemistry and Molecular Biophysics, Washington University School of Medicine | Pioneers in Biomedical Research Seminar Series | Co-Sponsored by the Fralin Biomedical Research Institute Cancer Research Group
-
Home ItemIn Person Seminar: Building and Maintaining Biological Tubes , home
Jan. 19, 2024, 11 a.m. | Ondine Cleaver, Ph.D., Professor, Molecular Biology, University of Texas Southwestern Medical Center | Pioneers in Biomedical Research Seminar Series | Co-Sponsored by the Fralin Biomedical Research Institute Center for Vascular and Heart Research
-
Home ItemLong Covid: the Lasting Legacy of the COVID-19 Pandemic , home
Jan. 25, 2024, 5:30 p.m. (Reception at 5 p.m.) | Ziyad Al-Aly, M.D., FASN, Chief of Research and Development Service, Director, Clinical Epidemiology Center, VA St. Louis Health Care Systems | Maury Strauss Distinguished Public Lecture